• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

mTOR inhibition in glioblastoma: requiem for a dream?

作者信息

Babak Sam, Mason Warren P

机构信息

Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

出版信息

Neuro Oncol. 2018 Apr 9;20(5):584-585. doi: 10.1093/neuonc/noy034.

DOI:10.1093/neuonc/noy034
PMID:29608764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5892149/
Abstract
摘要

相似文献

1
mTOR inhibition in glioblastoma: requiem for a dream?胶质母细胞瘤中的mTOR抑制：梦想的挽歌？
Neuro Oncol. 2018 Apr 9;20(5):584-585. doi: 10.1093/neuonc/noy034.
2
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.依维莫司、替莫唑胺与放疗用于新诊断胶质母细胞瘤患者的II期试验：NCCTG N057K
Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.
3
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.依维莫司联合吉非替尼治疗转移性去势抵抗性前列腺癌患者：1/2期研究结果及信号通路意义
Cancer. 2015 Nov 1;121(21):3853-61. doi: 10.1002/cncr.29578. Epub 2015 Jul 15.
4
Role of mTOR in glioblastoma.雷帕霉素靶蛋白（mTOR）在胶质母细胞瘤中的作用。
Gene. 2016 Jan 10;575(2 Pt 1):187-90. doi: 10.1016/j.gene.2015.08.060. Epub 2015 Sep 1.
5
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.18F-FLT PET 作为依维莫司抑制顺铂耐药卵巢肿瘤模型中 mTOR 时药物疗效的替代标志物。
J Nucl Med. 2010 Oct;51(10):1559-64. doi: 10.2967/jnumed.109.073288. Epub 2010 Sep 16.
6
UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.UCP2 抑制诱导 ROS/Akt/mTOR 轴：GAPDH 核转位在京尼平/依维莫司抗癌协同作用中的作用。
Free Radic Biol Med. 2017 Dec;113:176-189. doi: 10.1016/j.freeradbiomed.2017.09.022. Epub 2017 Sep 27.
7
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.mTOR 抑制剂 RAD001 增强了替莫唑胺诱导的胶质母细胞瘤细胞系中的自噬性细胞死亡。
Anticancer Res. 2013 May;33(5):1845-51.
8
Oscillatory mTOR inhibition and Treg increase in kidney transplantation.肾移植中振荡性mTOR抑制与调节性T细胞增加
Clin Exp Immunol. 2015 Nov;182(2):230-40. doi: 10.1111/cei.12669. Epub 2015 Aug 28.
9
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.新型PI3K-AKT-mTOR抑制剂可克服胰腺神经内分泌肿瘤长期获得性依维莫司耐药性。
Br J Cancer. 2016 Mar 15;114(6):650-8. doi: 10.1038/bjc.2016.25.
10
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.双mTORC1/2抑制剂增强mTOR抑制剂依维莫司在培养乳腺癌细胞系中的生长抑制反应
PLoS One. 2015 Jul 6;10(7):e0131400. doi: 10.1371/journal.pone.0131400. eCollection 2015.

引用本文的文献

1
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.多形性胶质母细胞瘤：对发病机制、关键信号通路及治疗策略的见解
Mol Cancer. 2025 Feb 26;24(1):58. doi: 10.1186/s12943-025-02267-0.
2
A Systematic Review of the Metabolism of High-Grade Gliomas: Current Targeted Therapies and Future Perspectives.高级别脑胶质瘤的代谢：当前的靶向治疗与未来展望的系统综述。
Int J Mol Sci. 2024 Jan 5;25(2):724. doi: 10.3390/ijms25020724.
3
Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment.揭示 mTOR 靶向治疗的新途径：胶质母细胞瘤治疗的进展。
Int J Mol Sci. 2023 Oct 6;24(19):14960. doi: 10.3390/ijms241914960.
4
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.将 FDA 批准的药物重新用作胶质母细胞瘤细胞中治疗诱导的侵袭伪足活性的抑制剂。
Mol Cell Biochem. 2023 Jun;478(6):1251-1267. doi: 10.1007/s11010-022-04584-0. Epub 2022 Oct 27.
5
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.成人高级别胶质瘤中的小分子抑制剂：从过去到未来
Front Oncol. 2022 Jun 17;12:911876. doi: 10.3389/fonc.2022.911876. eCollection 2022.
6
Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.患者来源的肿瘤类器官用于指导复发性胶质母细胞瘤的个体化药物治疗。
Int J Mol Sci. 2022 Jun 12;23(12):6572. doi: 10.3390/ijms23126572.
7
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).胶质母细胞瘤中的信号通路和治疗方法（综述）。
Int J Oncol. 2022 Jun;60(6). doi: 10.3892/ijo.2022.5359. Epub 2022 Apr 21.
8
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.靶向胶质母细胞瘤中的 RTK-PI3K-mTOR 轴：最新进展。
Int J Mol Sci. 2021 May 5;22(9):4899. doi: 10.3390/ijms22094899.
9
Autophagy Modulators Profoundly Alter the Astrocyte Cellular Proteome.自噬调节剂深刻改变星形胶质细胞的细胞蛋白质组。
Cells. 2020 Mar 26;9(4):805. doi: 10.3390/cells9040805.
10
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.第二代 mTOR 抑制剂在恶性脑胶质瘤治疗中的双刃剑作用。
Int J Mol Sci. 2019 Sep 10;20(18):4474. doi: 10.3390/ijms20184474.

本文引用的文献

1
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.一项新诊断胶质母细胞瘤中依维莫司联合放化疗的随机 II 期研究：NRG 肿瘤学 RTOG 0913 的结果。
Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209.
2
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.RTOG 0913：每日依维莫司（RAD001）联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤患者的 1 期研究。
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):880-4. doi: 10.1016/j.ijrobp.2013.04.036. Epub 2013 May 29.
3
Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.两阶段设计在 II 期癌症临床试验替代假设下的最优性。
Contemp Clin Trials. 2010 Nov;31(6):572-8. doi: 10.1016/j.cct.2010.07.008. Epub 2010 Aug 1.
4
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).依维莫司与吉非替尼治疗复发性胶质母细胞瘤（GBM）的一项试点研究。
J Neurooncol. 2009 Mar;92(1):99-105. doi: 10.1007/s11060-008-9741-z. Epub 2008 Nov 19.
5
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.替西罗莫司（CCI-779）治疗复发性多形性胶质母细胞瘤的II期试验：一项北中部癌症治疗组的研究。
J Clin Oncol. 2005 Aug 10;23(23):5294-304. doi: 10.1200/JCO.2005.23.622. Epub 2005 Jul 5.
6
Gene expression profiling and genetic markers in glioblastoma survival.胶质母细胞瘤生存中的基因表达谱分析与遗传标志物
Cancer Res. 2005 May 15;65(10):4051-8. doi: 10.1158/0008-5472.CAN-04-3936.
7
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.Rictor是mTOR的一种新型结合伴侣，它定义了一条对雷帕霉素不敏感且不依赖于Raptor的调节细胞骨架的途径。
Curr Biol. 2004 Jul 27;14(14):1296-302. doi: 10.1016/j.cub.2004.06.054.
8
Primary brain tumours in adults.成人原发性脑肿瘤
Lancet. 2003 Jan 25;361(9354):323-31. doi: 10.1016/S0140-6736(03)12328-8.
9
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.mTOR与猛禽蛋白相互作用形成一种对营养敏感的复合物，该复合物向细胞生长机制发出信号。
Cell. 2002 Jul 26;110(2):163-75. doi: 10.1016/s0092-8674(02)00808-5.